inappropriate ADH syndrome: A syndrome characterized by abnormal secretion of antidiuretic hormone in conjunction with neoplastic growth occurring anywhere in the body.
Syndrome of inappropriate secretion of antidiuretic hormone
DOID EFO Endpoint Browser PheWeb
E4_ANTIDIU
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
176 |
4. Check minimum number of eventsNone |
176 |
5. Include endpointsNone |
176 |
6. Filter based on genotype QC (FinnGen only) |
176 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E22
- Name in latin
- Syndroma secretionis impropriae hormonis antidiuretici
Similar endpoints
↥List of similar endpoints to
Syndrome of inappropriate secretion of antidiuretic hormone
based on the number of shared cases.
Similar with more cases:
- Hyperfunction of pituitary gland
- Exclusions for E4_PCOS_BROAD
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1631 | 971 | 648 |
| Only index persons | 1405 | 854 | 551 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 71.56 | 74.37 | 67.48 |
| Only index persons | 72.04 | 74.92 | 67.57 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 176 | 93 | 83 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | 69.29 | 69.51 | 69.05 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 157
- Matched controls
- 1570
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E22.2
ICD-10 Finland
Syndrome of inappropriate secretion of antidiuretic hormone
+∞
210.6
151
*
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
101.6
101.1
108
33
H02AB09
ATC
hydrocortisone; systemic
23.7
13.7
19
9
S06.5
ICD-10 Finland
Traumatic subdural haemorrhage
9.3
10.7
22
27
N03AX14
ATC
levetiracetam; systemic
14.7
9.9
16
12
G40.9
ICD-10 Finland
Epilepsy, unspecified
13.5
9.6
16
13
AA1AD
NOMESCO Finland
CT of head and brain
3.1
9.4
64
283
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
25.8
9.0
12
5
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
6.5
9.0
23
40
S06.3
ICD-10 Finland
Focal brain injury
29.3
8.6
11
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.3
8.5
50
197
E22.1
ICD-10 Finland
Hyperprolactinaemia
+∞
8.4
8
*
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
18.4
8.2
12
7
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
23.5
8.1
11
5
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
12.7
7.7
13
11
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
83.8
7.5
8
*
N05BA04
ATC
oxazepam; oral
2.8
7.3
56
258
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.3
7.1
38
137
R11
ICD-10 Finland
Nausea and vomiting
4.3
7.1
26
69
N03AG01
ATC
valproic acid; systemic, rectal
6.2
7.0
18
32
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.4
7.0
37
132
D64.9
ICD-10 Finland
Anaemia, unspecified
3.8
6.9
29
88
S02.11
ICD-10 Finland
Fracture of base of skull, open
41.9
6.8
8
*
N06AX11
ATC
mirtazapine; oral
2.6
6.8
65
339
N05CF01
ATC
zopiclone; oral
2.5
6.6
68
369
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.5
6.6
66
351
A06AD11
ATC
lactulose; oral
3.1
6.4
38
147
2536X
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Other disorders of neurohypophysis
+∞
6.3
6
*
R53
ICD-10 Finland
Malaise and fatigue
2.6
6.1
48
224
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.6
6.0
27
86
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
105
127
19.02
90.93
3.4
1.7
412.5
387.3
nmol/l
0.45
94
112
85
367
3.55
15.30
2.7
2.0
2.8
3.2
mg/l
1.19
69
314
124
725
3.40
12.80
9.0
6.4
1.2
1.2
mmol/l
0.45
95
606
102
560
2.95
11.24
3.0
2.5
122.7
123.2
ug/l
0.01
84
504
108
681
2.52
8.06
9.1
5.6
1.2
1.2
mmol/l
0.29
98
606
120
804
2.55
7.72
11.0
9.1
5.0
4.2
e9/l
1.63
107
706
11
15
7.76
7.64
1.8
1.8
28.3
18.3
ug/l
0.34
11
15
25
78
3.57
7.01
7.6
6.3
24.0
25.0
mmol/l
0.62
25
78
100
638
2.31
6.88
4.2
4.5
33.4
35.3
g/l
2.85
91
593
12
22
5.78
6.38
1.1
1.0
—
—
—
0
0
15
34
4.73
6.37
1.9
2.1
15.8
15.1
%
—
6
17
11
19
6.11
6.19
1.8
1.5
92.3
89.2
%
1.30
11
19
12
24
5.29
5.83
1.7
1.5
1.8
1.5
mmol/l
0.34
12
24
77
464
2.17
5.83
2.7
2.5
50.8
56.1
u/l
0.80
70
427
25
88
3.15
5.79
4.0
2.6
1.3
1.3
%
0.13
25
88
111
779
2.15
5.57
6.4
6.2
10.8
10.9
umol/l
0.03
103
728
70
413
2.15
5.53
6.0
3.4
0.5
0.6
e6/l
0.14
65
315
49
250
2.33
5.51
2.0
1.9
—
—
—
0
0
58
318
2.23
5.50
2.2
1.7
1644.1
1218.2
nmol/l
1.71
34
229
84
534
2.10
5.44
6.4
3.4
—
—
—
0
0
38
175
2.49
5.34
2.0
1.8
—
—
—
0
0
38
175
2.49
5.34
2.0
1.7
—
—
—
0
0
77
487
2.03
4.94
3.2
3.2
2.3
2.4
mmol/l
0.47
67
423
10
20
5.24
4.84
6.2
4.7
69.0
56.5
%
—
10
20
40
199
2.31
4.71
7.0
5.9
1.0
1.5
mmol/l
0.44
27
156
22
82
2.92
4.62
4.9
3.0
25.4
25.0
mmol/l
0.25
22
82
78
507
1.97
4.55
3.2
3.3
1331.4
1628.2
ng/l
0.25
65
429
39
195
2.28
4.53
7.1
5.9
4.8
5.1
kpa
0.67
34
185
39
195
2.28
4.53
7.1
5.9
12.3
11.6
kpa
0.36
34
185
137
1098
2.12
4.17
9.5
7.5
81.1
77.7
u/l
0.40
131
1009
34
166
2.30
4.16
3.3
5.6
238.5
239.8
u/l
0.02
28
154
89
622
1.87
4.04
5.7
4.2
47.8
48.5
ng/l
0.01
81
474
128
1013
1.97
3.88
6.5
3.9
15.9
15.0
pmol/l
2.57
116
891
83
574
1.84
3.84
3.3
2.2
82.9
79.3
nmol/l
0.49
74
488
13
39
3.52
3.84
1.5
1.3
—
—
—
0
0
11
30
3.84
3.70
1.4
1.7
—
—
—
0
0
58
363
1.89
3.64
1.7
1.6
21.8
21.1
nmol/l
0.13
49
295
13
41
3.34
3.57
1.3
1.6
—
—
—
0
0
8
13
6.39
3.54
1.4
1.1
—
—
—
0
0
78
544
1.78
3.41
8.0
4.4
—
—
—
0
0
31
158
2.17
3.41
6.6
3.5
—
—
—
0
0
10
27
3.87
3.40
1.3
1.7
—
—
—
0
0
10
27
3.87
3.40
1.3
1.5
—
—
—
0
0
11
32
3.60
3.39
1.2
1.5
—
—
—
0
0
109
840
1.78
3.36
3.5
3.3
55.0
50.9
u/l
0.14
101
775
12
38
3.32
3.28
1.3
1.7
—
—
—
0
0
21
92
2.46
3.25
5.0
3.9
2.2
1.7
mmol/l
0.20
16
71
9
20
4.68
3.16
1.3
1.4
—
—
—
0
0
15
56
2.83
3.15
3.3
2.6
—
—
—
0
0
6
8
7.71
3.08
1.2
1.0
—
—
—
0
0
93
701
1.69
2.96
7.2
4.3
0.0
0.0
estimate
0.00
30
111
24
117
2.22
2.94
5.8
5.9
24.4
24.3
mmol/l
0.01
19
109
83
609
1.69
2.91
2.5
2.0
97.7
94.4
pmol/l
0.23
37
303
12
43
2.92
2.70
2.7
2.3
24.7
24.7
mmol/l
0.01
12
33
123
1013
1.71
2.69
6.2
4.1
16.1
13.4
mm/h
1.00
115
909
91
695
1.64
2.66
9.2
5.7
0.0
0.0
estimate
0.00
30
116
57
386
1.71
2.65
8.3
4.5
0.0
0.0
estimate
0.00
30
112
9
25
3.74
2.61
1.2
1.1
—
—
—
0
0
90
690
1.62
2.56
7.3
4.2
0.0
0.0
estimate
0.00
30
118
8
21
3.94
2.49
1.4
1.8
—
—
—
0
0
6
12
5.13
2.42
1.2
1.0
—
—
—
0
0
6
12
5.13
2.42
1.2
1.0
—
—
—
0
0
28
159
1.90
2.31
1.9
3.0
6.2
8.6
umol/l
0.53
22
129
5
9
5.68
2.23
2.0
2.2
—
—
—
0
0
18
89
2.14
2.14
1.4
1.4
—
—
—
0
0
44
295
1.66
2.08
2.2
1.9
434.5
459.5
pmol/l
0.25
33
241
44
296
1.65
2.05
3.4
3.0
2.5
2.5
mmol/l
0.13
39
259
8
27
3.05
1.96
1.3
1.3
—
—
—
0
0
9
33
2.82
1.96
1.1
1.4
—
—
—
0
0
5
11
4.64
1.95
1.0
1.1
—
—
—
0
0
5
11
4.64
1.95
2.0
2.0
—
—
—
0
0
6
16
3.84
1.95
2.0
1.2
—
—
—
0
0
6
16
3.84
1.95
2.2
1.1
—
—
—
0
0
7
22
3.27
1.90
1.4
1.7
—
—
—
0
0
90
727
1.49
1.83
2.8
2.7
—
—
—
0
0
81
641
1.49
1.82
5.0
4.2
—
—
—
0
0
20
110
1.92
1.82
1.6
2.5
0.2
0.2
g/l
0.57
15
103
7
25
2.87
1.67
1.1
1.1
—
—
—
0
0
6
20
3.07
1.59
1.5
1.7
—
—
—
0
0
17
94
1.89
1.53
3.0
3.4
69.3
82.7
ng/l
—
10
82
150
1374
1.62
1.46
30.4
16.0
26.1
25.3
mg/l
0.12
137
1111
5
16
3.18
1.45
1.0
1.4
—
—
—
0
0
6
22
2.79
1.44
1.2
1.5
—
—
—
0
0
37
262
1.52
1.38
5.0
2.9
0.7
1.1
e6/l
0.79
32
159
19
114
1.75
1.35
2.3
1.6
—
—
—
0
0
6
24
2.55
1.31
2.0
1.6
—
—
—
0
0
10
48
2.15
1.30
1.6
1.3
—
—
—
0
0
8
35
2.35
1.28
2.1
1.4
—
—
—
0
0
8
35
2.35
1.28
1.9
1.6
—
—
—
0
0
8
35
2.35
1.28
1.9
1.6
—
—
—
0
0
137
1247
1.45
1.21
7.4
4.7
2.0
2.0
mu/l
0.00
124
1099
154
1438
1.57
1.16
41.3
18.9
4.1
4.0
mmol/l
3.30
149
1391
33
244
1.43
1.01
5.6
3.0
0.8
2.4
e6/l
1.52
28
144
17
109
1.62
0.98
4.2
3.4
59.6
60.5
ml/min/173m2
—
7
48
25
180
1.45
0.88
16.6
8.0
—
—
—
0
0
6
30
2.03
0.88
1.2
1.2
—
—
—
0
0
41
324
1.35
0.86
1.5
1.7
1.7
1.5
mg/l
0.16
33
255
11
65
1.74
0.84
1.6
3.2
—
—
—
0
0
41
334
1.30
0.70
3.1
2.3
—
—
—
0
0
13
86
1.55
0.68
1.8
1.5
—
—
—
0
0
46
383
1.27
0.67
2.5
3.1
300.0
7964.9
umol/l
2.21
31
313
18
129
1.44
0.66
2.3
2.4
254.8
207.6
ng/l
0.17
18
111
22
288
0.73
0.66
2.4
2.9
0.6
0.7
ug/l
0.85
17
190
8
49
1.66
0.63
1.3
1.9
—
—
—
0
0
123
1306
0.81
0.60
4.5
4.6
1.5
1.5
mmol/l
1.25
110
1176
35
285
1.28
0.60
7.5
3.6
18.0
189.4
ng/l
1.59
30
235
34
276
1.29
0.60
1.3
1.2
1.4
0.8
u/ml
—
7
66
34
411
0.79
0.58
3.5
4.5
20.2
21.6
%
0.30
20
204
126
1183
1.23
0.57
28.6
17.3
33.9
39.1
%
3.34
77
797
6
38
1.60
0.55
1.2
1.5
—
—
—
0
0
150
1438
1.29
0.54
15.0
10.9
26.0
24.4
u/l
0.23
145
1369
129
1349
0.84
0.44
5.1
5.3
2.4
2.6
mmol/l
2.17
116
1219
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
32
374
0.82
0.41
1.6
1.7
1.2
1.3
mmol/l
0.28
27
309
19
152
1.28
0.39
3.1
2.6
5.1
5.1
ug/l
0.00
14
135
15
187
0.78
0.34
3.7
4.7
43.0
31.7
%
—
10
120
121
1262
0.87
0.34
4.0
4.2
1.1
1.3
mmol/l
2.40
108
1132
126
1310
0.87
0.33
4.3
4.7
4.3
4.5
mmol/l
2.23
113
1191
7
54
1.31
0.31
1.3
1.9
—
—
—
0
0
20
168
1.21
0.28
1.5
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
14
165
0.84
0.20
1.6
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
—
—
0
0
6
76
0.78
0.16
2.0
1.9
—
—
—
0
0
131
1285
1.08
0.12
32.1
15.2
81.0
75.7
ml/min/173m2
1.93
118
1034
49
508
0.95
0.07
4.5
5.1
1.7
2.3
ug/l
1.07
43
441
134
1323
1.05
0.07
5.6
5.0
6.2
6.1
mmol/l
0.17
119
1186
21
203
1.04
0.01
1.3
1.3
18.6
31.8
iu/ml
—
10
66
129
1289
1.00
0.00
7.1
6.3
41.3
40.8
mmol/mol
0.20
118
1188
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
8.1
—
0
5
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
7
71
0.99
0.00
1.7
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
6
60
1.00
0.00
1.5
2.1
—
—
—
0
0
5
58
0.86
0.00
1.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_ANTIDIU and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ANTIDIU | 2.117 [1.65, 2.72] | < 0.001 |
| Birth year | 0.994 [0.98, 1.0] | 0.177 |
During the follow-up period (1.1.1998 — 31.12.2019), 348 out of 767 females with E4_ANTIDIU died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ANTIDIU | 3.366 [2.32, 4.88] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 270 out of 507 males with E4_ANTIDIU died.
Mortality risk
Mortality risk for people of age
years, who have E4_ANTIDIU.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.198% | 0.597% |
| 5 | 1.064% | 3.778% |
| 10 | 2.882% | 8.794% |
| 15 | 5.999% | 16.438% |
| 20 | 10.228% | 26.295% |
Relationships between endpoints
↥Index endpoint: E4_ANTIDIU – Syndrome of inappropriate secretion of antidiuretic hormone
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data